Latest Mergers And Acquisitions News

Next Science has obtained a crucial ASX waiver allowing it to return surplus capital to shareholders following its $50 million asset sale, despite expected share price declines below 20 cents.

360 Capital Group (ASX, TGP) has received an unconditional on-market takeover bid from TT Investments at $0.31 per stapled security. The Independent Board Committee unanimously recommends acceptance, supported by an Independent Expert's fair and reasonable opinion.

Zoono Group Limited has responded to ASX queries confirming ongoing collaboration with OSY Group Limited, acknowledging delays in meeting sales targets but highlighting steady contract progress and future order potential.

Globe Metals & Mining has issued over 56 million shares to Director Bo Tan, settling nearly all of an outstanding loan and achieving a fully debt-free status. This financial milestone positions the company strongly for advancing its Kanyika Niobium Project.

The Supreme Court of New South Wales has approved Southern Cross Media's acquisition of Seven West Media, setting the stage for a significant media industry consolidation early next year.

Latrobe Magnesium Limited has received a $6.29 million R&D tax rebate from the ATO, using the funds to reduce debt and progress its magnesium production plants in Australia and Malaysia.

Wingara AG Limited has arranged a $250,000 unsecured loan facility from NAOS Asset Management entities, featuring a convertible note option that could reshape its capital structure.

Scorpion Minerals has executed a binding option agreement to acquire the Old Prospect tenements within its Pharos Gold Project, adding a JORC-compliant resource of over 21,600 ounces of gold. The acquisition consolidates tenure along a highly prospective 5km structural corridor in Western Australia’s Murchison region.

Chimeric Therapeutics has raised $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, while initiating a strategic reset to sharpen focus and reduce costs.

Metgasco has pushed back the deadline for Vintage Energy’s commitment to acquire its stake in the Odin and Vali Gas Fields, extending the timeline while keeping the overall transaction completion date intact.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Neurizon Therapeutics has locked in a $44 million funding package to fully support its lead drug NUZ-001 in the HEALEY ALS Platform Trial, marking a critical step toward potential regulatory approval and broader neurodegenerative applications.